Evidence map›Paper›PMID 39601149›Full record

ArticleDisease models & mechanisms2024

It's about time: the heterochronic background for the 2024 Nobel Prize in Physiology or Medicine.

Bruce Wightman

Abstract readHistorical Article
In one paragraph

Article in Disease models & mechanisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bruce WightmanBiology Department, Muhlenberg College, Allentown, PA 18104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun "for the discovery of microRNA and its role in post-transcriptional gene regulation". The award celebrates the discovery of small regulatory miRNAs and their mRNA targets, published over three decades ago. The groundwork for this discovery was laid during the early 1980s, when Ambros began studying mutations that caused heterochronic defects in the nematode Caenorhabditis elegans - or shifts in the temporal identities of cells. A major impetus to study the heterochronic genes of C. elegans was to gain mechanistic understanding of how developmental stages are specified - a fascinating question in basic and evolutionary biology. Asking fundamental biological questions with no immediate application to human health ultimately led to the discovery of a new type of RNA, which had broad implications for understanding and treating human disease.

Indexed as

Caenorhabditis elegansNobel PrizeAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansMedicineMicroRNAsPhysiologyMicroRNAs

Identifiers

PMID39601149
PMCPMC11625885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.